Sign in or create an account to add this stock to your watchlist.
About AmpliPhi Biosciences (NYSEAMERICAN:APHB)
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:APHB
CUSIPN/A
Phone+1-804-8272524
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,050.00%
Return on Equity-31.85%
Return on Assets-21.63%
Miscellaneous
EmployeesN/A
Outstanding Shares16,460,000
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions
What is AmpliPhi Biosciences' stock symbol?
AmpliPhi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."
How were AmpliPhi Biosciences' earnings last quarter?
AmpliPhi Biosciences (NYSEAMERICAN:APHB) posted its earnings results on Wednesday, March, 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.11. The biotechnology company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. AmpliPhi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%. View AmpliPhi Biosciences' Earnings History.
When is AmpliPhi Biosciences' next earnings date?
What price target have analysts set for APHB?
1 brokers have issued 12 month price targets for AmpliPhi Biosciences' shares. Their predictions range from $6.00 to $6.00. On average, they anticipate AmpliPhi Biosciences' share price to reach $6.00 in the next twelve months. View Analyst Ratings for AmpliPhi Biosciences.
Are investors shorting AmpliPhi Biosciences?
AmpliPhi Biosciences saw a drop in short interest in May. As of May 15th, there was short interest totalling 858,583 shares, a drop of 7.7% from the April 30th total of 929,998 shares. Based on an average daily volume of 108,394 shares, the days-to-cover ratio is presently 7.9 days. Currently, 5.5% of the company's stock are sold short.
Who are some of AmpliPhi Biosciences' key competitors?
Some companies that are related to AmpliPhi Biosciences include Ergomed (ERGO), Cardiome Pharma (COM), OncoCyte (OCX), InMed Pharmaceuticals (IMLFF), Navidea Biopharmaceuticals (NAVB), Botanix Pharmaceuticals (BOT), IntelGenx Technologies (IGX), BELLUS Health (BLU), Medicenna Therapeutics (MDNA), Destiny Pharma (DEST), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), OptiBiotix Health (OPTI) and Scancell (SCLP).
Who are AmpliPhi Biosciences' key executives?
AmpliPhi Biosciences' management team includes the folowing people:
- Dr. Paul C. Grint, Chief Exec. Officer & Director (Age 60)
- Mr. Steven R. Martin, Sr. VP & CFO (Age 57)
- Dr. Igor P. Bilinsky Ph.D., Sr. VP & COO (Age 45)
- Mr. Michael Scott Salka, Consultant (Age 56)
- Dr. Alexander Gaidamaka Ph.D., D.V.M, VP of Chemistry, Manufacturing and Control
Has AmpliPhi Biosciences been receiving favorable news coverage?
News coverage about APHB stock has been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AmpliPhi Biosciences earned a media sentiment score of 0.14 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are AmpliPhi Biosciences' major shareholders?
AmpliPhi Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
SABBY MANAGEMENT, LLC
(7.78%) and Sabby Management LLC (5.05%). Company insiders that own AmpliPhi Biosciences stock include Jeremy Curnock Cook and Randal J Kirk. View Institutional Ownership Trends for AmpliPhi Biosciences.
Which institutional investors are buying AmpliPhi Biosciences stock?
How do I buy shares of AmpliPhi Biosciences?
Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AmpliPhi Biosciences' stock price today?
One share of APHB stock can currently be purchased for approximately $1.21.
How big of a company is AmpliPhi Biosciences?
AmpliPhi Biosciences has a market capitalization of $21.87 million.
How can I contact AmpliPhi Biosciences?
AmpliPhi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.
MarketBeat Community Rating for AmpliPhi Biosciences (APHB)
MarketBeat's community ratings are surveys of what our community members think about AmpliPhi Biosciences and other stocks. Vote "Outperform" if you believe APHB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days.
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for AmpliPhi Biosciences in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 395.87%. The high price target for APHB is $6.00 and the low price target for APHB is $6.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.00 | $6.00 | $6.00 | $7.50 |
| Price Target Upside: | 395.87% upside | 282.17% upside | 450.46% upside | 772.09% upside |
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Consensus Price Target History
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 5/16/2018 | HC Wainwright | Set Price Target | Buy | $6.00 |  |
| 1/24/2017 | Roth Capital | Reiterated Rating | Buy | | |
(Data available from 5/27/2016 forward)
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Earnings History and Estimates Chart
AmpliPhi Biosciences (NYSEAMERICAN APHB) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/13/2018 | | | | | | | | |
| 5/15/2018 | Q1 2018 | ($0.19) | ($0.24) | $0.10 million | | View | Listen | |
| 3/14/2018 | Q4 2017 | ($0.36) | ($0.25) | $0.03 million | $0.02 million | View | N/A | |
| 11/14/2017 | Q3 2017 | ($0.46) | ($0.09) | $0.03 million | $0.04 million | View | N/A | |
| 8/14/2017 | Q2 2017 | ($0.80) | ($0.78) | | $0.03 million | View | N/A | |
| 5/15/2017 | Q1 2017 | ($8.20) | ($1.94) | $0.10 million | $0.03 million | View | N/A | |
| 3/27/2017 | Q4 2016 | ($3.30) | ($3.20) | $0.10 million | $0.02 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($3.80) | ($3.20) | $0.10 million | $0.03 million | View | N/A | |
| 8/15/2016 | Q216 | ($0.66) | ($0.78) | $0.10 million | $0.10 million | View | Listen | |
| 5/12/2016 | Q116 | ($0.68) | ($0.82) | $0.11 million | $0.11 million | View | N/A | |
| 3/30/2016 | Q415 | ($0.40) | ($0.43) | $0.12 million | $0.13 million | View | N/A | |
| 11/16/2015 | Q3 2015 | ($2.00) | ($3.00) | $0.10 million | $0.14 million | View | N/A | |
| 8/13/2015 | Q2 2015 | ($7.50) | ($5.70) | | $0.10 million | View | N/A | |
| 5/15/2015 | Q1 2015 | ($5.00) | ($5.00) | | $0.10 million | View | N/A | |
| 4/15/2015 | Q4 2014 | ($5.00) | ($5.00) | | $0.10 million | View | N/A | |
| 11/18/2014 | | ($0.02) | $0.06 | | | View | N/A | |
| 9/24/2014 | | ($0.02) | ($0.01) | | | View | N/A | |
| 9/12/2014 | Q2 2014 | ($10.00) | ($5.00) | | $0.31 million | View | N/A | |
| 5/20/2014 | Q1 2014 | ($10.00) | ($30.00) | | | View | N/A | |
| 6/1/2010 | Q4 2009 | | $42.50 | | | View | N/A | |
| 11/16/2009 | Q3 2009 | | $16.00 | | | View | N/A | |
| 8/12/2009 | Q2 2009 | | $345.50 | | | View | N/A | |
| 5/7/2009 | Q1 2009 | | ($35.50) | | | View | N/A | |
| 3/31/2009 | Q4 2008 | | ($64.00) | | | View | N/A | |
| 8/6/2008 | Q2 2008 | ($85.00) | ($95.50) | | | View | N/A | |
| 5/7/2008 | Q1 2008 | ($150.00) | ($81.00) | | | View | N/A | |
| 3/25/2008 | Q4 2007 | | ($94.00) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AmpliPhi Biosciences (NYSEAMERICAN APHB) Insider Trading and Institutional Ownership History
AmpliPhi Biosciences (NYSEAMERICAN APHB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/22/2018 | Jeremy Curnock Cook | Director | Buy | 354,315 | $1.54 | $545,645.10 | 330 | |
| 12/29/2016 | Randal J Kirk | Major Shareholder | Sell | 177,020 | $0.48 | $84,969.60 | | |
| 4/8/2016 | Jeremy Curnock Cook | Director | Buy | 239,753 | $2.36 | $565,817.08 | | |
| 10/6/2015 | Louis Drapeau | Director | Buy | 10,000 | $4.39 | $43,900.00 | 10,000 | |
| 10/5/2015 | Michael Scott Salka | CEO | Buy | 4,200 | $4.75 | $19,950.00 | 4,200 | |
| 10/5/2015 | Wendy S Johnson | Insider | Buy | 1,000 | $4.43 | $4,430.00 | 1,000 | |
| 3/16/2015 | Randal J Kirk | Major Shareholder | Buy | 13,939,392 | $0.17 | $2,369,696.64 | | |
(Data available from 1/1/2013 forward)
AmpliPhi Biosciences (NYSEAMERICAN APHB) News Headlines
| Source: |
|
AmpliPhi Biosciences (NYSEAMERICAN:APHB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AmpliPhi Biosciences (NYSEAMERICAN:APHB) Income Statement, Balance Sheet and Cash Flow Statement
AmpliPhi Biosciences (NYSEAMERICAN APHB) Stock Chart for Sunday, May, 27, 2018
Loading chart…
